Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

This study has suspended participant recruitment.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ) Identifier:
First received: March 23, 2010
Last updated: October 19, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)